Valuation: AstraZeneca PLC

Market Cap 287B 444,327B 261B 241B 218B 411B 26,957B 425B 2,898B 1,148B 14,466B 1,077B 1,054B 45,822B P/E 2026 *
24.3x
P/E 2027 * 20.9x
Enterprise Value 308B 476,569B 280B 258B 233B 441B 28,913B 456B 3,108B 1,232B 15,516B 1,155B 1,131B 49,147B EV / Sales 2026 *
4.86x
EV / Sales 2027 * 4.46x
Free-Float
96.36%
Yield 2026 *
1.8%
Yield 2027 * 1.91%
1 day+0.29%
1 week-0.32%
Current month+0.32%
1 month+15.72%
3 months+25.87%
6 months+15.08%
Current year+9.82%
1 week 76,550
Extreme 76550
78,575
1 month 66,450
Extreme 66450
81,150
Current year 60,650
Extreme 60650
81,150
1 year 60,650
Extreme 60650
81,150
3 years 24,288
Extreme 24288
81,150
5 years 5,438.5
Extreme 5438.5
81,150
10 years 214.5
Extreme 214.5
81,150
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Chief Operating Officer 55 01/06/2015
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.29%-0.32% - - 287B
-0.14%-0.55%+39.42%+140.73% 1,275B
-0.44%-0.21%+40.38%+87.05% 680B
-0.32%-0.59%+24.85%+111.24% 521B
-0.82%+1.02%+41.33%+70.83% 389B
-0.00%-3.13%+54.44%+40.94% 356B
-1.40%-0.68%+26.26%+58.81% 305B
-1.48%-0.69%+1.44%+34.39% 287B
-0.50%-1.34%+34.32%+72.95% 250B
+2.13%-0.75%+36.67%+124.77% 208B
Average -0.32%+0.51%+33.23%+82.41% 475B
Weighted average by Cap. -0.37%+0.76%+35.30%+96.16%

Financials

2026 *2027 *
Net sales 63.38B 98,088B 57.58B 53.2B 48.05B 90.68B 5,951B 93.87B 640B 253B 3,193B 238B 233B 10,115B 67.39B 104,304B 61.23B 56.57B 51.1B 96.43B 6,328B 99.82B 680B 270B 3,396B 253B 248B 10,756B
Net income 11.69B 18,096B 10.62B 9.81B 8.87B 16.73B 1,098B 17.32B 118B 46.77B 589B 43.87B 42.95B 1,866B 13.58B 21,014B 12.34B 11.4B 10.29B 19.43B 1,275B 20.11B 137B 54.31B 684B 50.95B 49.87B 2,167B
Net Debt 20.83B 32,242B 18.93B 17.49B 15.8B 29.81B 1,956B 30.86B 210B 83.32B 1,050B 78.17B 76.52B 3,325B 13.65B 21,123B 12.4B 11.46B 10.35B 19.53B 1,281B 20.22B 138B 54.59B 688B 51.21B 50.13B 2,178B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
16/11/26 ARS 77,475.00 +0.29% 205
13/11/26 ARS 77,250.00 +0.16% 262
12/11/26 ARS 77,125.00 -0.10% 429
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
185.09USD
Average target price
215.52USD
Spread / Average Target
+16.44%